American Association for Cancer Research
Browse
00085472can152887-sup-157051_2_supp_3448170_t5km0b.pdf (3.85 MB)

Supplementary Figure S7-9 from Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer

Download (3.85 MB)
journal contribution
posted on 2023-03-30, 23:53 authored by Qianhui Dou, Hai-Ning Chen, Kui Wang, Kefei Yuan, Yunlong Lei, Kai Li, Jiang Lan, Yan Chen, Zhao Huang, Na Xie, Lu Zhang, Rong Xiang, Edouard C. Nice, Yuquan Wei, Canhua Huang

Supplementary Figure S7-9

Funding

Basic Research Program of China

National Science and Technology Major Project

NSFC

Sichuan Science-Technology Innovative Research Team

History

ARTICLE ABSTRACT

Breast cancer is the most common cancer among women worldwide, yet successful treatment remains a clinical challenge. Ivermectin, a broad-spectrum antiparasitic drug, has recently been characterized as a potential anticancer agent due to observed antitumor effects. However, the molecular mechanisms involved remain poorly understood. Here, we report a role for ivermectin in breast cancer suppression by activating cytostatic autophagy both in vitro and in vivo. Mechanistically, ivermectin-induced autophagy in breast cancer cells is associated with decreased P21-activated kinase 1 (PAK1) expression via the ubiquitination-mediated degradation pathway. The inhibition of PAK1 decreases the phosphorylation level of Akt, resulting in the blockade of the Akt/mTOR signaling pathway. In breast cancer xenografts, the ivermectin-induced cytostatic autophagy leads to suppression of tumor growth. Together, our results provide a molecular basis for the use of ivermectin to inhibit the proliferation of breast cancer cells and indicate that ivermectin is a potential option for the treatment of breast cancer. Cancer Res; 76(15); 4457–69. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC